Ferrario et al. (Ferrario et al., 2005) observed that the ACE2 mRNA increased in the heart during ACE inhibition or losartan treatment, which corroborates the results from Sommerstein and Grani (Sommerstein & Gräni, 2020) that ACE inhibitors may be a potential risk factor for fatal COVID‐19. The gene discussed is ACE; the disease is COVID-19.